Alpha 2.0
Login Register
» Authors » Eric Legangneux

Eric Legangneux

Explore the profile of Eric Legangneux including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 205
Followers 0
Related Specialties
Pharmacology
General Medicine
Neurology
Top 10 Co-Authors
Kasra Shakeri-Nejad
Anne Gardin
Mike Ufer
Srikanth Neelakantham
Uday Kiran Veldandi
Zhenzhong Su
Nicole Pezous
Angela Dodman
Vassilios Aslanis
Ralph Woessner
Published In
Int J Clin Pharmacol Ther
Clin Ther
Br J Clin Pharmacol
Int J Neuropsychopharmacol
J Clin Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat
Vormfelde S, Pezous N, Lefevre G, Kolly C, Neumann U, Jordaan P, et al.
Clin Transl Sci . 2020 Jun; 13(6):1316-1326. PMID: 32583957
Umibecestat, an orally active β-secretase inhibitor, reduces the production of amyloid beta-peptide that accumulates in the brain of patients with Alzheimer's disease. The echocardiogram effects of umibecestat, on QTcF (Fridericia-corrected...
2.
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects
Shakeri-Nejad K, Gardin A, Gray C, Neelakantham S, Dumitras S, Legangneux E
Clin Ther . 2020 Jan; 42(1):175-195. PMID: 31926605
Purpose: The goal of this study was to assess the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of intravenous (IV) siponimod in healthy subjects. Methods: This randomized, open-label study was...
3.
Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects
Gardin A, Gray C, Neelakantham S, Huth F, Davidson A, Dumitras S, et al.
Eur J Clin Pharmacol . 2018 Aug; 74(12):1593-1604. PMID: 30105453
Purpose: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects. Methods: This was a confirmatory, open-label, multiple-dose two-period study in...
4.
Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
Gardin A, Ufer M, Legangneux E, Rossato G, Jin Y, Su Z, et al.
Clin Pharmacokinet . 2018 Aug; 58(3):349-361. PMID: 30088221
Objectives: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and...
5.
Metabolism and Disposition of Siponimod, a Novel Selective S1P/S1P Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism
Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, et al.
Drug Metab Dispos . 2018 May; 46(7):1001-1013. PMID: 29735753
Siponimod, a next-generation selective sphingosine-1-phosphate receptor modulator, is currently being investigated for the treatment of secondary progressive multiple sclerosis. We investigated the absorption, distribution, metabolism, and excretion (ADME) of a...
6.
Impact of siponimod on vaccination response in a randomized, placebo-controlled study
Ufer M, Shakeri-Nejad K, Gardin A, Su Z, Paule I, Marbury T, et al.
Neurol Neuroimmunol Neuroinflamm . 2017 Sep; 4(6):e398. PMID: 28955715
Objective: To evaluate effects of siponimod on response to T-cell-dependent (influenza) and T-cell-independent (pneumococcal polysaccharide vaccine [PPV-23]) vaccinations in healthy participants. Methods: In this double-blind, placebo-controlled, parallel-group study, each participant...
7.
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study

Gardin A, Dodman A, Kalluri S, Neelakantham S, Tan X, Legangneux E, et al.
Int J Clin Pharmacol Ther . 2016 Nov; 55(1):54-65. PMID: 27841151
Objective: To investigate the pharmacokinetics (PK), safety, and tolerability of siponimod and selected inactive metabolites (M3 and M5) in subjects with varying degrees of renal impairment (RI) compared to demographically...
8.
Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056)
Ufer M, Sagkriotis A, Salunke A, Ganesan S, Tisserant A, Dodman A, et al.
Clin Ther . 2016 Nov; 38(12):2589-2597. PMID: 27823869
Purpose: The conduct of thorough QTc (TQT) studies is often challenging with compounds that are characterized by limited tolerability in healthy individuals. This is applicable to several central nervous system...
9.
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study

Shakeri-Nejad K, Aslanis V, Veldandi U, Gardin A, Zaehringer A, Dodman A, et al.
Int J Clin Pharmacol Ther . 2016 Jul; 55(1):41-53. PMID: 27443658
Objective: To assess the pharmacokinetics (PK), safety, and tolerability of siponimod and major metabolites in subjects with mild, moderate, and severe hepatic impairment (HI) compared with demographically-matched healthy subjects (HS)....
10.
Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects
Legangneux E, Shakeri-Nejad K, Aslanis V, Sagkriotis A, Pezous N, Brendani B, et al.
Clin Ther . 2016 Feb; 38(3):631-45.e1. PMID: 26916566
Purpose: The goal of this study was to investigate the effect of siponimod treatment re-initiation on the initial negative chronotropic effects and cardiac rhythm after variable drug discontinuation periods. Methods:...